**Research Article**

**JAZF1 Inhibits Adipose Tissue Macrophages and Adipose Tissue Inflammation in Diet-Induced Diabetic Mice**

Fanping Meng,1 Yao Lin,1 Min Yang,1 Minyan Li,1 Gangyi Yang,2 Po Hao,3 and Ling Li1

1The Key Laboratory of Laboratory Medical Diagnostics in the Ministry of Education and Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical University, Chongqing 400010, China
2Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China
3Department of Laboratory Medicine, Chongqing Three Gorges Medical College, Chongqing 400020, China

Correspondence should be addressed to Ling Li; liling31@hotmail.com

Received 31 August 2017; Revised 19 December 2017; Accepted 28 December 2017; Published 22 March 2018

**Background.** Juxtaposed with another zinc finger gene 1 (JAZF1) affects gluconeogenesis, insulin sensitivity, lipid metabolism, and inflammation, but its exact role in chronic inflammation remains unclear. This study aimed to examine JAZF1 overexpression in vivo on adipose tissue macrophages (ATMs).

**Methods.** Mouse models of high-fat diet- (HFD-) induced insulin resistance were induced using C57BL/6J and JAZF1-overexpressing (JAZF1-OX) mice. The mice were randomized (8–10/group) to C57BL/6J mice fed regular diet (RD) (NC group), C57BL/6J mice fed HFD (HF group), JAZF1-OX mice fed RD (NJ group), and JAZF1-OX mice fed HFD (HJ group). Adipose tissue was harvested 12 weeks later. ATMs were evaluated by flow cytometry. Inflammatory markers were evaluated by ELISA.

**Results.** JAZF1-OX mice had lower blood lipids, blood glucose, body weight, fat weight, and inflammatory markers compared with HF mice (all \(P < 0.05\)). JAZF1 overexpression decreased ATM number and secretion of proinflammatory cytokines. JAZF1 overexpression decreased total CD4+ T cells, active T cells, and memory T cells and increased Treg cells. JAZF1 overexpression downregulated IFN-\(\gamma\) and IL-17 levels and upregulated IL-4 levels. JAZF1 overexpression decreased MHCII, CD40, and CD86 in total ATM, CD11c+ ATM, and CD206+ ATM.

**Conclusions.** JAZF1 limits adipose tissue inflammation by limiting macrophage populations and restricting their antigen presentation function.

**1. Introduction**

Type 2 diabetes mellitus (T2DM) is a chronic endocrine disorder characterized by hyperglycemia resulting from insulin resistance and deficiency [1]. In patients with T2DM, the chronic hyperglycemic state can lead to multiorgan damage, eventually resulting in renal, neurologic, and cardiovascular complications, among others [1]. The 2014 worldwide prevalence of T2DM was 9% in men and 7.9% in women [2]. In 2010, in China, the prevalence of T2DM was 12.4% in men and 11% in women, and the prevalence of prediabetes was 50.1% [3]. Obesity, hypertension, dyslipidemia, a family history of diabetes, and lifestyle factors are risk factors of T2DM [1, 4]. Over the last few decades, scientific evidence highlighted the complex metabolic and immune pathways that underlie the pathogenesis, progression, and clinical course of T2DM [5].

Recent studies demonstrated that inflammation plays a pivotal role in the occurrence and development of insulin resistance and T2DM [6, 7]. Proinflammatory cytokines (particularly interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-\(\alpha\)) are chronically increased in diabetic patients and contribute to T2DM development, progression, and complications [3].

Juxtaposed with another zinc finger gene 1 (JAZF1) is an inhibitor of the nuclear receptor subfamily 2, group C, member 2 signaling pathway and has been shown to be involved in gluconeogenesis, insulin sensitivity, lipid metabolism, and inflammation [8]. JAZF1 plays an important role in glucose homeostasis and its overexpression enhances glucose tolerance and insulin sensitivity [8]. The exact mechanisms are poorly understood, but a recent study showed that JAZF1 prevents lipogenesis and systemic inflammatory diseases in transgenic mice [9].
Obesity induces a state of chronic low-grade inflammation, mediated in part by macrophages and other immune cells that populate the adipose tissue, contributing to β-cell dysfunction and insulin resistance [10]. The numbers of adipose tissue macrophages (ATMs) increase with body mass and they are the primary cell type regulating inflammation in the context of insulin resistance [11]. The ATMs regulate the secretion of IL-1β and IL-18, which play important roles in the development of obesity-related insulin resistance [12]. Macrophage recruitment factors also contribute to ATM infiltration and further development of insulin resistance [13]. Dendritic cells also play important roles (mainly antigen presentation) in the regulation of adipose tissue inflammation [14].

Insulin resistance is associated with immune system dysfunction and chronic low-grade inflammation, but the exact role of JAZF1 in T2DM is still poorly understood. Therefore, this study aimed to determine how JAZF1 affects chronic low-grade inflammation, ATMs, and antigen presentation in a mouse model of diet-induced insulin resistance.

2. Materials and Methods

2.1. Animals. The mouse model of diet-induced insulin resistance was used to investigate the role of JAZF1 in vivo. All animal procedures were approved by the ethical committee of Chongqing Medical University. C57BL/6J wild-type mice and JAZF1-OX mice (4 weeks of age; 10–18 g) were used, which is a CMV-promoter-based model [8, 15, 16]. All mice were of the C57BL/6J background. The mice were kept at 18–25°C and humidity of 40–60% under a 12-hour light-dark cycle. The C57BL/6J wild-type mice were obtained from Chongqing Medical University and the JAZF1-OX mice from the West China Center of Medical Sciences, Sichuan University. The mice were placed together in the same cages and acclimatized for 1 week before any experiment.

All mice had free access to water and food throughout the course of the experiment. During the first week, all mice were fed a regular diet (RD). One week later, the mice were randomly divided into four groups of 8–10 mice and fed either a RD or a high-fat diet (HFD): RD-fed wild-type mice as normal control (NC group), HFD-fed wild-type mice (HF group), RD-fed JAZF1-OX mice (NJ group), and HFD-fed JAZF1-OX mice (HJ group) (Supplementary Tables 1 and 2).

After 12 weeks, the mice were sacrificed and weighed. Blood was collected from the left ventricle. Liver, muscle, and heart were obtained. The adipose tissue was harvested from the testicles or womb, kidney, and the abdomen. For GTT, right jugular vein catheterization was conducted 3 days before GTT. GTT was performed when the body weight of the mice recovered to 90% of their preoperative weight. Mice were fasted for 8 h and weighed. Fasting blood samples were collected and fasting blood glucose levels were measured. Intraperitoneal GTT (glucose load of 1.5 g/kg body weight) was performed and blood glucose levels were measured at 15, 30, 60, and 120 min. Blood samples were collected. Plasma was separated by centrifugation and stored at −80°C for plasma insulin (Plns) determination. These tests were carried out in the waking state.

2.3. Metabolic Parameters. Blood glucose and lipid metabolism indexes were measured in all mice. Serum total cholesterol (TC), triglycerides (TG), and glucose were measured using a Cobas E600 Automatic Analyzer (Roche Diagnostics, Basel, Switzerland).

2.4. Adipose Tissue Isolation. Total adipose tissue was cut using ophthalmic scissors and placed in PBS with 0.25% pancreatin. The mixture was incubated under constant agitation in a 37°C water bath for 1 h. RPMI 1640 culture medium with 2% BSA (Sigma, St. Louis, MO, USA) was added. The mixture was passed through a 40 μm nylon cell strainer (BD Biosciences, Franklin Lake, NJ, USA). Hemolysin was added to remove the erythrocytes. The samples were prepared into single-cell suspensions for flow cytometry.

To monitor the recruitment of macrophages into adipose tissue after 12 weeks of HFD and to look for potential mechanisms of glucose metabolism abnormalities in obese JAZF1-OX mice, the total numbers of ATM, CD206+ ATM, and CD11c+ ATM were compared among the four groups. TNF-α and IL-1β were measured to detect ATM activity.

2.5. Flow Cytometry. The serum inflammation markers were measured according to the manufacturer’s instructions using the BD CBA Mouse Th1/Th2 Cytokine Kit (BD Biosciences, Franklin Lake, NJ, USA). The ATM and T cells (1 × 10⁶ cells) were labeled with fluorochrome-conjugated monoclonal antibodies: anti-mouse CD3, CD4, CD11b, CD11c, CD206, F4/80, CD25, CD44, CD69, CD52, FOXP3, MHCI, CD40, CD86, IL-6, IL-1β, IL-4, IL-13, IL-17, IL-10, TNF-α, and IFN-γ (BD Biosciences, Franklin Lake, NJ, USA). For intracellular staining, the cells were activated with PMA/ionomycin (BD Biosciences, Franklin Lake, NJ, USA) according to the manufacturer’s instructions. Cells were analyzed with the FACSCalibur Flow Cytometer (BD Biosciences, Franklin Lake, NJ, USA) and the FCAP Array software. Flow cytometry analyses were performed according to standard procedures and according to the manufacturer’s instructions.

2.6. Statistical Analysis. Data were presented as mean ± SEM and analyzed using one-way ANOVA with the Bonferroni post hoc test. Relationships between pairs of variables were assessed using the Pearson correlation test. Statistical significance was assumed at P < 0.05. Statistical analyses were performed using SPSS 18.0 (IBM, Armonk, NY, USA).
| Metabolic Parameter       | NC         | NJ         | HF         | HJ         |
|--------------------------|------------|------------|------------|------------|
| Body weight (g)          | 26.31 ± 0.81 | 26.59 ± 0.91 | 36.09 ± 1.43 | 31.21 ± 0.81 |
| Epididymal fat weight (g) | 0.48 ± 0.04 | 0.58 ± 0.08 | 2.82 ± 0.51 | 0.89 ± 0.04 |
| Glucose (mM)             | 6.30 ± 0.43 | 5.94 ± 0.43 | 8.15 ± 0.36 | 6.96 ± 0.32 |
| TC (mM)                  | 2.56 ± 0.09 | 2.17 ± 0.09 | 3.82 ± 0.08 | 3.07 ± 0.07 |
| TG (mM)                  | 0.58 ± 0.04 | 0.51 ± 0.04 | 0.73 ± 0.04 | 0.72 ± 0.03 |

Values are presented as mean ± SEM (n = 6 per group). TC: total cholesterol; TG: triglycerides; NC: wild-type mice fed a regular diet; HF: wild-type mice fed a high-fat diet; NJ: JAZF1-OX mice fed a regular diet; HJ: JAZF1-OX mice fed a high-fat diet. *P < 0.05 versus the NC group; ΔP < 0.05 versus the HF group.

Figure 1: Blood glucose and insulin levels during ITT and GTT. (a) The ratio of the initial blood glucose levels during ITT. (b) Time course of the blood glucose levels during GTT. (c) Time course of the blood insulin levels during GTT. *P < 0.05 versus the NC group. ΔP < 0.05 versus the HF group. Values are presented as mean ± SEM (n = 8–10/group).

3. Results

3.1. JAZF1-OX Mice Have Lower Blood Lids, Blood Glucose, Body Weight, and Fat Weight. The body weight, fat weight, blood glucose, TC, and TG were measured to examine the effects of JAZF1 on metabolic parameters. As shown in Table 1, the body weight, epididymal fat weight, blood glucose, TC, and TG were higher in the HF group compared with the NC group (all P < 0.05). All these parameters were lower in the HJ group compared with the HF group (all P < 0.05).

3.1.1. Insulin Tolerance Test (ITT) and Glucose Tolerance Test (GTT). ITT and GTT were performed to examine the effect of JAZF1 on glucose metabolism. For ITT, after intraperitoneal injection of insulin, the mice showed lower blood glucose levels compared with baseline (0 min) (P < 0.05). The blood glucose levels in the NJ group at 30 and 60 min were significantly lower than those in the NC group (P < 0.05). After injection of insulin, mice in the HJ group showed significantly decreased blood glucose levels at all time points (15, 30, 45, and 60 min) compared to the HF group (P < 0.05 or P < 0.01) (Figure 1(a)).

For the GTT analysis, after intraperitoneal injection of glucose, blood glucose levels were significantly increased in all groups compared with baseline (0 min) (P < 0.05). The blood glucose levels of the NJ group were significantly lower than those in the mice of the NC group at 15 min (P < 0.05),
CD11c+ ATM numbers, TNF-α, the effect of JAZF1 on immune cells. Total ATM numbers, secretion of TNF-α.

3.3. JAZFI Decreases ATM Numbers and Their Cytokine Secretion. The numbers of total ATM and CD11c+ ATM and the secretion of TNF-α and IL-1β were measured to assess the effect of JAZFI on immune cells. Total ATM numbers, CD11c+ ATM numbers, TNF-α, and IL-1β in the HF group were higher than those in the NC group (all \( P < 0.05 \)), while these markers were lower in the HJ group than in the HF group (all \( P < 0.05 \)). For CD206+ ATM, the levels were lower in the HF group compared with the NC and HJ groups (all \( P < 0.05 \)), suggesting that JAZFI can decrease CD11c+ ATMs but enhances CD206+ ATMs. The parameters in the NJ and NC groups were not significantly different \( (P > 0.05) \) (Figures 3(a)–3(e), Supplementary Figure 1).

The correlations between the ATM numbers and fat mass, body weight, and glucose were examined. Figure 3(f) shows that, in HFD mice, the total ATM numbers were positively correlated with fat mass \( (r^2 = 0.85) \), body weight \( (r^2 = 0.86) \), and fasting blood glucose \( (r^2 = 0.77) \).

3.4. JAZFI Lowers Total CD4+ T Cells, CD69+ Active T Cells, and CD44+ Memory T Cells and Enhances CD25+ FOXP3+ Treg Cells. As JAZFI-OX ATMs produce less CD4+ T cell-activating cytokines (Table 2), these cells were evaluated. The total CD4+ T cell number, CD69+ activated T cell number, and CD44+ memory T cells were higher in the HF group than in the NC group \( (P < 0.05) \) and lower in the HJ group compared with the HF group \( (P < 0.05) \). With regard to the CD25+ FOXP3+ Treg cell numbers and total T cell numbers, the HF group had lower counts than the NC and HJ groups \( (P < 0.05) \). The parameters in the NJ and NC groups were not significantly different \( (P > 0.05) \) (Figures 4(a)–4(e), Supplementary Figure 2).

There were correlations between CD4+ AT T cell numbers, fat mass, body weight, and fasting glucose. The total CD4+ AT T cell counts were positively correlated with fat mass \( (r^2 = 0.94) \), body weight \( (r^2 = 0.52) \), and fasting blood glucose levels \( (r^2 = 0.47) \) (Figure 4(f)).

3.5. JAZFI Downregulates IFN-γ and IL-17 Levels and Upregulates IL-4 Levels. IFN-γ and IL-17 were measured to examine the effect of JAZFI on the markers of inflammation. CD4+ T cells in the HF group secreted more IFN-γ and IL-17 than those in the NC and HJ groups. The HF group had lower levels of IL-4 than the NC and HJ groups, while the NC and NJ groups showed no significant differences in these parameters \( (P > 0.05) \) (Figure 5, Supplementary Figure 3).
but were increased in CD206+ ATM ($P < 0.05$) (Figures 6(a)–6(i)). MHCII, CD40, and CD86 in total ATM and CD11c+ ATM in the HF group were higher than those in the NC group ($P < 0.05$) but lower than those in the HJ group ($P < 0.05$). CD206+ ATMs in the HF group were lower than those in the NC and HJ groups. There were no significant differences between the NJ and NC groups ($P > 0.05$) (Figures 6(a)–6(i), Supplementary Figure 4).

4. Discussion

JAZF1 affects gluconeogenesis, insulin sensitivity, lipid metabolism, and inflammation, but its exact role in chronic inflammation remains unclear. Therefore, this study examined whether JAZF1 overexpression in vivo can decrease ATMs. JAZF1 limits adipose tissue inflammation by limiting macrophage populations and restricting their antigen presentation function. This would play a role in the development and progression of T2DM.

In recent years, studies have highlighted many aspects of the complex interactions among genetic, environmental, metabolic, and immune factors that contribute to the development and progression of T2DM. We now know that diseases that fall into the metabolic syndrome spectrum, such as T2DM and obesity, are associated with dysfunctional immunity and low low-grade inflammation, as shown by increased levels of proinflammatory cytokines such as TNF-$\alpha$, IL-6, and chemotactic factors (e.g., CCL5 and CCL8) [6, 7, 12]. Inhibition of key proinflammatory cytokines has been shown, in vivo, to protect rodents from insulin resistance and T2DM [17]. This proinflammatory response has been further associated with an imbalanced T cell subtype differentiation, particularly decreased CD4+ subtypes traditionally associated with chronic inflammation [18].

The present study showed that, compared with normal control mice fed a RD, mice fed a HFD (HF group) had higher levels of IFN-$\gamma$ and IL-17 expressed by CD4+ T cells, while IL-4 produced from Treg cells was reduced. In addition, the total numbers of CD4+ T cells and of activated and memory T cell were higher in mice fed a HFD than in those fed a RD, which suggests changes in CD4+ T cell subtype differentiation taking place in adipose tissue. Feeding high fat diets to mice gave rise to low-grade inflammation in the adipose tissue, leading in turn to the recruitment of immune cells and production of proinflammatory cytokines leading to insulin resistance [19–21]. Controlling low-grade inflammation in adipocytes should be considered as a targeted approach to limit the pathogenesis of metabolic diseases.
Studies in rats show that increased plasma FFA can activate muscle NF-κB signaling [22], which can lead to higher levels of proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and MCP-1 [23]. This increase in plasma MCP-1 can promote monocyte migration from the blood to the adipose tissue. When macrophages settle in the adipose tissue, they differentiate into inflammatory macrophages, which can release a great amount of inflammatory factors [24, 25]. ATF2 has a similar effect, and total and phosphorylated ATF2 are highly expressed in infiltrated macrophages [26]. Macrophages can be classified into M1 and M2. M1 macrophages are activated by the classical pathway and promote inflammation, while M2 macrophages regulate inflammation and are activated by alternative pathways. A previous study showed that the macrophages’ subtype differentiation was changed in the adipose tissue, where M2 macrophages tended to transform into M1 macrophages [27]. Proinflammatory ATMs, which express CD11c+ (a classical marker for activated M1), are generally increased, hereby leading to inflammation and insulin resistance [28–31], resulting in a reduction of the relative number of CD206+ macrophages (alternatively activated or M2 macrophages), which are predominantly anti-inflammatory [32, 33]. In the present study, the HF group had higher levels of total ATM counts, CD11c+ ATM, and TNF-α and IL-1β compared to mice fed a RD. The CD206+ ATM parameters were lower in the HF group than in the NC and HJ groups, supporting the hypothesis that the macrophage activation pathways had switched to favor proinflammatory macrophages. In JAZF1-OX mice fed a HFD, CD4+ T cell and macrophage counts, secretion, and subtype differentiation were at the opposite of the results observed in wild-type mice fed the same diet. Nevertheless, a recent study suggests that IL-6 regulates M2 differentiation in ATM in obesity [34]. Additional studies are necessary to elucidate the exact mechanisms involved in M1/M2 differentiation.

Previous studies showed that JAZF1 is closely associated with insulin secretion and sensitivity in T2DM, as well as with β-cell function [35, 36]. Previous studies by our group found that JAZF1 could promote lipid accumulation of 3T3-L1 cells and upregulate the expression of GLUT1 in hepatocytes [9, 15, 37]. JAZF1 transgenic mice showed that overexpression of JAZF1 can downregulate PEPCK and G6Pase levels (which are key enzymes in glucose metabolism) and increase the insulin receptor substrate-1 (IRS-1) level and phosphorylation [9, 15, 37], suggesting that JAZF1 may increase the rate of basal
Figure 5: Inflammatory markers of CD4 T cells in mice (from epididymal fat). Levels of (a) IL-4, (b) IL-17, and (c) IFN-γ from epididymal fat cell suspension. Values are presented as mean ± SEM (n = 8–10/group). * P < 0.05 versus the NC group; △ P < 0.05 versus the HF group.

Our previous work also shows that upregulation of JAZF1 in hepatocytes can, in vivo, inhibit the expression of proinflammatory cytokines such as TNF-α, MCP-1, and IL-8 via the action of palmitic acid [9, 15, 37]. In the meantime, JNK, p38 MAPK, and NF-κB may also take part in this process. The present study supports the accumulating evidence of the association between JAZF1 and inflammation. Moreover, JAZF1 appears to be a key player in metabolic gene expression and T2DM development and, as such, its role needs to be further studied to clarify its implications in inflammation [38, 39].

A study showed that the adipose tissue in CD40-deficient animals has elevated cytokine levels and inflammatory cell infiltrates, particularly of macrophages and T cells [40], suggesting an important role of TH1 cells in regulating inflammation and insulin resistance in obesity. CD4+ and CD8+ T cells populate the human adipose tissue and the Th1:Th2 balance is highly associated with systemic inflammation and insulin resistance; in addition, MHCII and costimulators CD86 and CD40 play essential roles in obesity-induced adipose tissue inflammation [41].

Taken together, these findings suggest that the adaptive immune system could be a potential mediator between obesity and insulin resistance or inflammation [42–45].

MHCII and costimulatory molecules (CD86 and CD40) required for ATM-mediated CD4+ T cell activation were evaluated and the results showed that they were significantly increased in JAZF1-OX ATM. In addition, MHCII, CD40, and CD86 in total ATM and CD11c+ ATM counts were higher in HFD-fed mice than in control mice and those in HFD-fed JAZF1-OX mice. Concerning CD206+ ATM, the parameters in the HF group were lower than in the NC and HJ groups. Nevertheless, much work is still necessary to examine the exact interactions between JAZF1 and specific immune cells. A previous study showed that JAZF1 transgenic mice have a natural resistance to HFD-induced obesity [39]. In addition, the same study showed that JAZF1 plays an important role in lipid homeostasis under HFD conditions [39]. Since overweight and blood lipids are involved in inflammation, JAZF1 overexpression could decrease the inflammatory state under HFD. Indeed, in the present study, no differences were observed between the NC and HJ groups, indicating that JAZF1 played some role in protecting the mice against the deleterious effects of HFD. The main differences were observed between the NC and HJ groups. Finally, the present study was not designed to identify the exact mechanisms involved in the observed effects of JAZF1 on immune cells. A previous study showed that the...
JNK pathway might be involved [9], providing a starting point for future experiments. Additional studies are necessary to address these issues.

5. Conclusions

HFD-fed JAZF1-OX mice showed lower levels of ATM, especially the CD11c+ ATM and the proinflammatory cytokines they secrete, compared with wild-type mice fed the same diet. Similar observations were made for CD4+ T cells and their proinflammatory cytokines, MHCII, CD40, and CD86. Taken together, these results suggest that JAZF1 can control ATMs by downregulating their antigen presentation function and lowering adipose tissue inflammation.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was supported by research grants from the National Natural Science Foundation of China (81270913 and 81300670).

Supplementary Materials

Supplementary Table 1: composition of the regular diet (RD) (per 1000 g). Supplementary Table 2: comparison of the weight and energy compositions between the regular diet (RD) and high-fat diet (HFD). Supplementary Figure 1: flow cytometry representation of gated (A) ATM (CD11b+F4/80+), (B) IL-1β, and (C) TNF-α intracellular staining in ATM and CD11c+ and CD206+ ATM. Supplementary Figure 2: flow cytometry representation of gated AT (A) CD4 T cells (CD3+ CD4+), (B) Treg T cells (CD25+ FOXP3+), (C) active T cells (CD4+ CD69+), (D) restrained T cells (CD4+ CD152+), and (E) memory T cells (CD4+ CD44+). Supplementary Figure 3: flow cytometry representation of gated AT CD4 T cells stained intracellularly with (A) IL-4 and (B) IL-17. Supplementary Figure 4: costimulatory molecule (CD40 and CD86) expression in gated total ATM, MHCII, and costimulatory molecule (CD40, CD80, and CD86) expression in gated CD11c+ ATM, MHCII, and costimulatory molecule (CD40, CD80, and CD86) expression in gated CD206+ ATM (n = 8–10/group). (Supplementary Materials)
References

[1] American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 37, supplement 1, pp. S81–S90, 2014.

[2] Collaboration NCDRF, “Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants,” The Lancet, vol. 387, pp. 1513–1530, 2016.

[3] Y. Xu, L. Wang, J. He et al., “Prevalence and control of diabetes in Chinese adults,” Journal of the American Medical Association, vol. 310, no. 9, pp. 948–958, 2013.

[4] P. W. F. Wilson, R. B. D’Agostino, H. Parise, L. Sullivan, and J. B. Meigs, “Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus,” Circulation, vol. 112, no. 20, pp. 3066–3072, 2005.

[5] J. A. Kolberg, T. Jørgensen, R. W. Gerwien et al., “Development of a type 2 diabetes risk model from a panel of serum biomarkers from the inter99 cohort,” Diabetes Care, vol. 32, no. 7, pp. 1207–1212, 2009.

[6] W. T. Cefalu, “Inflammation, insulin resistance, and type 2 diabetes: Back to the future?” Diabetes, vol. 58, no. 2, pp. 307–308, 2009.

[7] Å. Sjöholm and T. Nyström, “Inflammation and the etiology of type 2 diabetes,” Diabetes/Metabolism Research and Reviews, vol. 22, no. 1, pp. 4–10, 2006.

[8] L. Yuan, X. Luo, M. Zeng et al., “Transcription factor TIP27 regulates glucose homeostasis and insulin sensitivity in a PI3-kinase/Akt-dependent manner in mice,” International Journal of Obesity, vol. 39, no. 6, pp. 949–958, 2015.

[9] M. Yang, J. Dai, Y. Jia et al., “Overexpression of juxtaposed with another zinc finger gene 1 reduces proinflammatory cytokine release via inhibition of stress-activated protein kinases and nuclear factor-κB,” FEBS Journal, vol. 281, no. 14, pp. 3193–3205, 2014.

[10] L. K. Heilbronn and L. V. Campbell, “Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity,” Current Pharmaceutical Design, vol. 14, no. 12, pp. 1225–1230, 2008.

[11] J. Lee, “Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 Diabetes,” Archives of Pharmacal Research, vol. 36, no. 2, pp. 208–222, 2013.

[12] R. Stienstra, C. J. Tack, T.-D. Kanneganti, L. A. B. Joosten, and M. G. Netea, “The inflammasome puts obesity in the danger zone,” Cell Metabolism, vol. 15, no. 1, pp. 10–18, 2012.

[13] M. Spite, J. Hellmann, Y. Tang et al., “Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity,” The Journal of Immunology, vol. 187, no. 4, pp. 1942–1949, 2011.

[14] A. Bertola, T. Ciucci, D. Rousseau et al., “Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th1 responses in mice and patients,” Diabetes, vol. 61, no. 9, pp. 2238–2247, 2012.

[15] X. Li, M. Yang, H. Wang et al., “Overexpression of JAZF1 protected ApoE-deficient mice from atherosclerosis by inhibiting hepatic cholesterol synthesis via CREB-dependent mechanisms,” International Journal of Cardiology, vol. 177, no. 1, pp. 100–110, 2014.

[16] K. B. Bae, M. O. Kim, D. H. Yu et al., “Overexpression of Jazf1 induces cardiac malformation through the upregulation of pro-apoptotic genes in mice,” Transgenic Research, vol. 20, no. 5, pp. 1019–1031, 2011.

[17] H. Cucak, D. Vistisen, D. Witte, A. Philipsen, and A. Rosendahl, “Reduction of specific circulating lymphocyte populations with metabolic risk factors in patients at risk to develop type 2 diabetes,” PLoS ONE, vol. 9, no. 9, Article ID e107140, 2014.

[18] M. Jagannathan-Bogdan, M. E. McDonnell, H. Shin et al., “Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes,” The Journal of Immunology, vol. 186, no. 2, pp. 1162–1172, 2011.

[19] C. Varol, I. Zvibel, L. Spektor et al., “Long-acting glucose-dependent insulino-tropic polypeptide ameliorates obesity-induced adipose tissue inflammation,” The Journal of Immunology, vol. 193, no. 8, pp. 4002–4009, 2014.

[20] A. Chawla, K. D. Nguyen, and Y. P. S. Goh, “Macrophage-mediated inflammation in metabolic disease,” Nature Reviews Immunology, vol. 11, no. 11, pp. 738–749, 2011.

[21] O. Osborn and J. M. Olefsky, “The cellular and signaling networks linking the immune system and metabolism in disease,” Nature Medicine, vol. 18, no. 3, pp. 363–374, 2012.

[22] V. Braunersreuther, G. L. Viviani, F. Mach, and E. Montecucco, “Role of cytokines and chemokines in non-alcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 18, no. 8, pp. 727–735, 2012.

[23] M. J. Pagliassotti, Y. Wei, and D. Wang, “Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity,” Endocrinology, vol. 148, no. 7, pp. 3338–3345, 2007.

[24] J. S. Orr, A. J. Kennedy, and A. H. Hasty, “Isolation of adipose tissue immune cells,” Journal of Visualized Experiments, Article ID e50707, 2013.

[25] V. Nehra, P. Angulo, A. L. Buchman, and K. D. Lindor, “Nutritional and metabolic considerations in the etiology of non-alcoholic steatohepatitis,” Digestive Diseases and Sciences, vol. 46, no. 11, pp. 2347–2352, 2001.

[26] Y. Miyata, A. Fukushima, M. Otsuki, and I. Shimomura, “Expression of activating transcription factor 2 in inflammatory macrophages in obese adipose tissue,” Obesity, vol. 21, no. 4, pp. 731–736, 2013.

[27] N. N. Pejnovic, J. M. Pantic, I. P. Jovanovic et al., “Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets,” Diabetes, vol. 62, no. 6, pp. 1932–1944, 2013.

[28] C. N. Luneng, “Adipose tissue macrophages: A piece of the PAI of metabolic syndrome,” Science Translational Medicine, vol. 2, no. 20, pp. 20–ps7, 2010.

[29] C. N. Luneng, J. L. Bodzin, and A. R. Saltiel, “Obesity induces a phenotypic switch in adipose tissue macrophage polarization,” The Journal of Clinical Investigation, vol. 117, no. 1, pp. 175–184, 2007.

[30] C. N. Luneng, S. M. DeYoung, J. L. Bodzin, and A. R. Saltiel, “Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity,” Diabetes, vol. 56, no. 1, pp. 16–23, 2007.

[31] C. N. Luneng and A. R. Saltiel, “Inflammatory links between obesity and metabolic disease,” The Journal of Clinical Investigation, vol. 121, no. 6, pp. 2111–2117, 2011.

[32] S. Fujisaka, I. Usui, M. Ikutani et al., “Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages in an HIF-1α-dependent and HIF-1α-independent manner in obese mice,” Diabetologia, vol. 56, no. 6, pp. 1403–1412, 2013.
[33] K. Kambara, W. Ohashi, K. Tomita et al., "In vivo depletion of CD206+ M2 macrophages exaggerates lung injury in endotoxemic mice," *The American Journal of Pathology*, vol. 185, no. 1, pp. 162–171, 2015.

[34] J. Braune, U. Weyer, C. Hobusch et al., "IL-6 regulates M2 polarization and local proliferation of adipose tissue macrophages in obesity," *The Journal of Immunology*, vol. 198, no. 7, pp. 2927–2934, 2017.

[35] M. P. Fogarty, T. M. Panhuis, S. Vadlamudi, M. L. Buchkovich, and K. L. Mohlke, "Allele-specific transcriptional activity at type 2 diabetes-associated single nucleotide polymorphisms in regions of pancreatic islet open chromatin at the JAZF1 locus," *Diabetes*, vol. 62, no. 5, pp. 1756–1762, 2013.

[36] K. K. Alharbi, I. Ali Khan, R. Syed et al., "Association of JAZF1 and TSPAN8/LGR5 variants in relation to type 2 diabetes mellitus in a Saudi population," *Diabetology & Metabolic Syndrome*, vol. 7, no. 1, article no. 92, 2015.

[37] L. Li, Y. Yang, G. Yang et al., "The role of JAZF1 on lipid metabolism and related genes in vitro," *Metabolism - Clinical and Experimental*, vol. 60, no. 4, pp. 523–530, 2011.

[38] W. J. Hu, W. W. Shen, X. J. Li, J. Yao, Y. J. Jia, and X. Y. Fan, "Effect of JAZF1 over-expression on high-fat diet-induced non-alcoholic fatty liver disease," *Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology*, vol. 24, no. 8, pp. 596–600, 2016.

[39] W. Y. Jang, K. B. Bae, S. H. Kim et al., "Overexpression of Jazf1 reduces body weight gain and regulates lipid metabolism in high fat diet," *Biochemical and Biophysical Research Communications*, vol. 444, no. 3, pp. 296–301, 2014.

[40] C.-A. Guo, S. Kogan, S. U. Amano et al., "CD40 deficiency in mice exacerbates obesity-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance," *American Journal of Physiology-Renal Physiology*, vol. 304, no. 9, pp. E951–E963, 2013.

[41] I. M. Khan, X.-Y. Dai Perrard, J. L. Perrard et al., "Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency," *Atherosclerosis*, vol. 233, no. 2, pp. 419–428, 2014.

[42] T. McLaughlin, L.-F. Liu, C. Lamendola et al., "T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 34, no. 12, pp. 2637–2643, 2014.

[43] T. Deng, C. J. Lyon, L. J. Minze et al., "Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation," *Cell Metabolism*, vol. 17, no. 3, pp. 411–422, 2013.

[44] M. H. Y. Chng, M. N. Alonso, S. E. Barnes, K. D. Nguyen, and E. G. Engleman, "Adaptive immunity and antigen-specific activation in obesity-associated insulin resistance," *Meditators of Inflammation*, vol. 2015, Article ID 593075, 15 pages, 2015.

[45] Y. Mao, B. Wang, X. Xu, W. Du, W. Li, and Y. Wang, "Glycyrrhizin Acid Promotes M1 Macrophage Polarization in Murine Bone Marrow-Derived Macrophages Associated with the Activation of JNK and NF- B," *Meditors of Inflammation*, vol. 2015, Article ID 372931, 2015.